StoxPoly Medicure vs NATCO Pharma: share price & financials comparison
NSE: POLYMED vs NATCOPHARM · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Poly Medicure vs NATCO Pharma at a glance
Poly Medicure (POLYMED) has a market capitalisation of ₹16,342 Cr, against ₹14,445 Cr for NATCO Pharma (NATCOPHARM). Over the past year NATCO Pharma has returned -2.5%, compared with -18.1% for Poly Medicure. On valuation, NATCO Pharma trades at a lower P/E of 12.6 versus 51.3. NATCO Pharma earns a higher return on equity (12.4% vs 9.8%). Poly Medicure comes out ahead on growth, momentum and technicals. NATCO Pharma comes out ahead on size, valuation, profitability and financial health. Across the scored metrics below, Poly Medicure leads on 9 and NATCO Pharma on 9. On StoxGud's 10-point checklist, Poly Medicure scores 6/10 and NATCO Pharma scores 4/10.
| Metric | Poly Medicure | NATCO Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹16,342 Cr | ₹14,445 Cr |
| Revenue (latest FY) | ₹1,875 Cr | ₹4,078 Cr |
| Net profit (latest FY) | ₹322 Cr | ₹1,418 Cr |
| Valuation | ||
| P/E | 51.3 | 12.6 |
| P/B | 5.00 | 1.57 |
| Dividend yield | 0.22% | 0.62% |
| Profitability | ||
| Return on equity | 9.8% | 12.4% |
| Net profit margin | 14.9% | 32.8% |
| Operating margin | 22.7% | 30.2% |
| Growth | ||
| Revenue growth (YoY) | +30.8% | -44.7% |
| Net profit growth (YoY) | +3.6% | -57.0% |
| Revenue CAGR (multi-year) | +19.0% | +14.7% |
| Financial health | ||
| Debt to equity | 0.12 | 0.08 |
| Momentum | ||
| 1-month return | -0.2% | -0.4% |
| 1-year return | -18.1% | -2.5% |
| 3-year CAGR | +5.5% | +2.6% |
| 5-year CAGR | +12.2% | -1.5% |
| 10-year CAGR | +23.6% | +3.3% |
| Distance from 52W high | -21.9% | -33.1% |
| Technicals | ||
| RSI (14) | 52 | 62 |
| Price vs 200-day avg | +4.3% | -13.0% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Poly Medicure | NATCO Pharma |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 6/10 | 4/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Poly Medicure or NATCO Pharma?
Poly Medicure has a market cap of ₹16,342 Cr and NATCO Pharma has a market cap of ₹14,445 Cr as of 06 Nov 2026.
Which has a lower P/E, Poly Medicure or NATCO Pharma?
NATCO Pharma has the lower P/E: Poly Medicure trades at 51.3 and NATCO Pharma at 12.6.
Which gave better returns in the last year, Poly Medicure or NATCO Pharma?
NATCO Pharma did better: Poly Medicure returned -18.1% and NATCO Pharma returned -2.5% over one year.
Is Poly Medicure or NATCO Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Poly Medicure scores 6/10 and NATCO Pharma scores 4/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.